123 related articles for article (PubMed ID: 38295753)
61. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
62. EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
Okamura S; Yoshino H; Kuroshima K; Tsuruda M; Osako Y; Sakaguchi T; Yonemori M; Yamada Y; Tatarano S; Nakagawa M; Enokida H
BMC Cancer; 2021 Jan; 21(1):48. PubMed ID: 33430801
[TBL] [Abstract][Full Text] [Related]
63. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
Kuan FC; Li JM; Huang YC; Chang SF; Shi CS
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139437
[TBL] [Abstract][Full Text] [Related]
64. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
[TBL] [Abstract][Full Text] [Related]
65. Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
Jung JH; You S; Oh JW; Yoon J; Yeon A; Shahid M; Cho E; Sairam V; Park TD; Kim KP; Kim J
Cancer Lett; 2018 Nov; 437():1-12. PubMed ID: 30145203
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
67. FOXO1 inactivation induces cisplatin resistance in bladder cancer.
Ide H; Goto T; Teramoto Y; Mizushima T; Jiang G; Nagata Y; Inoue S; Baras AS; Kashiwagi E; Miyamoto H
Cancer Sci; 2020 Sep; 111(9):3397-3400. PubMed ID: 32678492
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
69. SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.
Qin Z; Tong H; Li T; Cao H; Zhu J; Yin S; He W
Int J Mol Med; 2021 Nov; 48(5):. PubMed ID: 34549307
[TBL] [Abstract][Full Text] [Related]
70. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
71. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
72. The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer.
Chen X; Liu M; Meng F; Sun B; Jin X; Jia C
J Cell Biochem; 2019 Jan; 120(1):243-252. PubMed ID: 30216500
[TBL] [Abstract][Full Text] [Related]
73. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
74. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
75. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
[TBL] [Abstract][Full Text] [Related]
76. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
[TBL] [Abstract][Full Text] [Related]
77. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
78. A PolH Transcript with a Short 3'UTR Enhances PolH Expression and Mediates Cisplatin Resistance.
Zhang J; Sun W; Ren C; Kong X; Yan W; Chen X
Cancer Res; 2019 Jul; 79(14):3714-3724. PubMed ID: 31064846
[TBL] [Abstract][Full Text] [Related]
79. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D; Abbosh P; Keliher D; Reardon B; Miao D; Mouw K; Weiner-Taylor A; Wankowicz S; Han G; Teo MY; Cipolla C; Kim J; Iyer G; Al-Ahmadie H; Dulaimi E; Chen DYT; Alpaugh RK; Hoffman-Censits J; Garraway LA; Getz G; Carter SL; Bellmunt J; Plimack ER; Rosenberg JE; Van Allen EM
Nat Commun; 2017 Dec; 8(1):2193. PubMed ID: 29259186
[TBL] [Abstract][Full Text] [Related]
80. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells.
Liu J; Bi J; Li Z; Li Z; Liu X; Kong C
Int J Mol Med; 2018 Mar; 41(3):1765-1773. PubMed ID: 29328435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
